|Articles|September 11, 2012

LIVE from PDA FDA Joint Regulatory Conference 2012

Be sure to follow our Twitter feed from this year’s PDA-FDA Joint Regulatory Conference, taking place in Baltimore.

Be sure to follow our Twitter feed from this year’s PDA-FDA Joint Regulatory Conference, taking place in Baltimore, at Twitter@PharmTechAngie or Twitter@PharmTechGroup. Today’s sessions focused on common regulatory citations (the word is that they haven’t changed much in the past 10 years), new ways to handle internal investigations from Big Pharma organizations such as Amgen and Abbott (including a bit of an audience stirup surrounding the management, or lack thereof, of Class I investigations), FDA encouragement of sending novel excipients in for review, best practices for selecting excipients for new drugs (including how to best deal with suppliers), updates on ICH Q11, and a lot of information on knowledge management, risk-based approaches (including QbD), and lifecycle approaches. More information to come tomorrow when the various FDA offices give their reports.


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.